Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
In this study led by researchers at Harvard Medical School, they report the first demonstration of prevention of severe clinical disease in a hamster model of SARS-CoV-2 that were provided with a single immunization of the adenovirus serotype 26 (Ad26) vaccine. The Ad26 vaccine utilizes a stabilized spike protein of the SARS-CoV-2 and in the United States this vaccine is commonly known as the Johnson and Johnson vaccine. This study, published in print in November 2020 contributed to the scientific body of evidence in animal models that enabled clinical vaccine trials that in turn led to emergency use approvals in the United States, Canada, and other countries. Researchers leveraged the Multiplex IHC module of HALO for evaluation of the percentage of SAR-N protein positive cells and for Iba-1 quantification. The Area Quantification IHC module was used to determine the percentage of SARS-CoV-2 sense or anti-sense probe or Mx1 protein as a function of area. The Cytonuclear IHC module and Area Quantification IHC modules were used in detection of MPO+ or CD3+ cells expressed as a proportion of total alveolar tissue.
Tostanoski LH, Wegmann F, Martinot AJ, Loos C, McMahan K, Mercado NB, Yu J, Chan CN, Bondoc S, Starke CE, Nekorchuk M, Busman-Sahay K, Piedra-Mora C, Wrijil LM, Ducat S, Custers J, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Lin Z, Mahrokhian SH, Nampanya F, Nityanandam R, Pessaint L, Porto M, ALi V, Benetiene D, Tevi K, Andersen H, Lewis MG, Schmidt AG, Lauffenburger DA, Alter G, Estes JD, Schuitemaker H, Zahn R, Barouch DH
Nature Medicine | First published 03 September 2020| DOI https://doi.org/10.1038/s41591-020-1070-6